Sphingolipid metabolizing enzymes as novel therapeutic targets.
Subcell Biochem
; 49: 487-522, 2008.
Article
en En
| MEDLINE
| ID: mdl-18751924
ABSTRACT
Pharmacological interference with sphingolipid metabolizing enzymes promises to provide novel ways to modulate cellular pathways relevant in multiple diseases. In this review, we focus on two sphingolipid signaling molecules, sphingosine-1-phosphate (S1P) and ceramide, as they are involved in cell fate decisions (survival vs. apoptosis) and in a wide range of pathophysiological processes. For S1P, we will discuss sphingosine kinases and S1P lyase as the enzymes which are crucial for its production and degradation, respectively, emphasizing the potential therapeutic usefulness of inhibitors of these enzymes. For ceramide, we will concentrate on acid sphingomyelinase, and critically review the substantial literature which implicates this enzyme as a worthwhile target for pharmacological inhibitors. It will become clear that the task to validate these enzymes as drug targets is not finished and many questions regarding the therapeutic usefulness of their inhibitors remain unanswered. Still this approach holds promise for a number of totally new therapies, and, on the way, detailed insight into sphingolipid signaling pathways can be gained.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Esfingolípidos
/
Esfingomielina Fosfodiesterasa
/
Esfingosina
/
Lisofosfolípidos
/
Ceramidas
/
Fosfotransferasas (Aceptor de Grupo Alcohol)
/
Aldehído-Liasas
/
Inhibidores Enzimáticos
/
Neoplasias
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Subcell Biochem
Año:
2008
Tipo del documento:
Article
País de afiliación:
Austria